We are live on
!
Find out more
AA
ALPS Advisors Portfolio holdings
AUM
$21.3B
1-Year Est. Return
21.71%
This Fund
S&P 500
This Quarter
Est. Return
+0.76%
1 Year Est. Return
+21.71%
3 Year Est. Return
+77.63%
5 Year Est. Return
+121.1%
10 Year Est. Return
+198.29%
AUM
$13.6B
AUM Growth
+$1.31B
(+11%)
Cap. Flow
+$1.24B
Cap. Flow
% of AUM
9.18%
Top 10 Holdings %
Top 10 Hldgs %
52.17%
Holding
753
New
79
Increased
425
Reduced
211
Closed
38
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ETP
Energy Transfer Partners L.p.
ETP
|
+$190M |
| 2 |
Enterprise Products Partners
EPD
|
+$96.4M |
| 3 |
MMP
Magellan Midstream Partners, L.P.
MMP
|
+$94.8M |
| 4 |
Plains All American Pipeline
PAA
|
+$81.9M |
| 5 |
BPL
Buckeye Partners, L.P.
BPL
|
+$76.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nucor
NUE
|
+$36.6M |
| 2 |
NOV
NOV
|
+$34.2M |
| 3 |
Qualcomm
QCOM
|
+$34.1M |
| 4 |
CenterPoint Energy
CNP
|
+$32.7M |
| 5 |
ConocoPhillips
COP
|
+$31.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Energy | 67.49% |
| 2 | Financials | 2.86% |
| 3 | Materials | 2.35% |
| 4 | Healthcare | 2.33% |
| 5 | Industrials | 1.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
KITE
176
DELISTED
Kite Pharma, Inc.
KITE
| $2.15M | 0.02% |
47,930
-15,297
| -24% | -$750K |
|
177
Ventas
VTR
$48.9B
| $2.1M | 0.02% |
33,556
-2,695
| -7% | -$171K |
|
178
Ligand Pharmaceuticals
LGND
$6.02B
| $2.04M | 0.02% |
32,195
-10,422
| -24% | -$658K |
|
179
Ironwood Pharmaceuticals
IRWD
$611M
| $1.93M | 0.01% |
150,500
-47,279
| -24% | -$597K |
|
|
JUNO
180
DELISTED
Juno Therapeutics, Inc.
JUNO
| $1.92M | 0.01% |
101,741
-33,110
| -25% | -$810K |
|
181
Boston Properties
BXP
$11B
| $1.85M | 0.01% |
14,700
-1,797
| -11% | -$223K |
|
|
SAGE
182
DELISTED
Sage Therapeutics
SAGE
| $1.82M | 0.01% |
35,716
-5,198
| -13% | -$245K |
|
|
FPRX
183
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $1.81M | 0.01% |
36,085
-8,718
| -19% | -$458K |
|
184
Vornado Realty Trust
VNO
$7.47B
| $1.71M | 0.01% |
20,269
-3,162
| -13% | -$249K |
|
185
Plains GP Holdings
PAGP
$5.23B
| $1.69M | 0.01% |
48,714
-86,551
| -64% | -$2.97M |
|
186
Agios Pharmaceuticals
AGIO
$2.16B
| $1.69M | 0.01% |
40,377
-8,125
| -17% | -$426K |
|
187
Supernus Pharmaceuticals
SUPN
$2.68B
| $1.67M | 0.01% |
66,251
-15,859
| -19% | -$354K |
|
|
DBVT
188
DBV Technologies
DBVT
$807M
| $1.63M | 0.01% |
4,633
-1,513
| -25% | -$543K |
|
189
Eldorado Gold
EGO
$8.31B
| $1.58M | 0.01% |
+98,437
| New | +$1.55M |
|
190
Host Hotels & Resorts
HST
$16.8B
| $1.58M | 0.01% |
84,010
+170
| +0.2% | +$2.87K |
|
|
RDUS
191
DELISTED
Radius Health, Inc.
RDUS
| $1.58M | 0.01% |
41,431
-13,493
| -25% | -$642K |
|
192
Digital Realty Trust
DLR
$73.7B
| $1.49M | 0.01% |
15,182
-621
| -4% | -$57.7K |
|
|
ONCE
193
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
| $1.48M | 0.01% |
29,573
-9,463
| -24% | -$507K |
|
194
Essex Property Trust
ESS
$18.9B
| $1.45M | 0.01% |
6,229
-746
| -11% | -$161K |
|
195
Realty Income
O
$61.2B
| $1.42M | 0.01% |
25,553
-3,127
| -11% | -$175K |
|
|
GGP
196
DELISTED
GGP Inc.
GGP
| $1.4M | 0.01% |
55,862
-6,433
| -10% | -$164K |
|
197
Healthpeak Properties
DOC
$15.4B
| $1.34M | 0.01% |
45,108
-9,721
| -18% | -$296K |
|
|
SA
198
Seabridge Gold
SA
$2.8B
| $1.3M | 0.01% |
159,879
+16,482
| +11% | +$162K |
|
|
KYNB
199
Kyntra Bio
KYNB
$28.5M
| $1.3M | 0.01% |
2,428
-774
| -24% | -$386K |
|
200
Emergent Biosolutions
EBS
$375M
| $1.28M | 0.01% |
38,918
-12,660
| -25% | -$380K |
|
Similar funds
PAG
MMH
IC
DSA
VARA
SC
CB
ALPS Advisors's Q4 2016 Portfolio in Review
As of Q4 2016, ALPS Advisors held 753 positions worth $13.6B, up 11% from $12.3B the previous quarter. Its ten largest holdings account for 52% of the portfolio.
ALPS Advisors deployed $1.24B of net new capital in Q4 2016, opening 79 new positions and adding to 425 existing holdings. Its largest new stake was Eli Lilly: 558,209 shares worth $41.1M.
By sector, the portfolio is most concentrated in Energy at 67% of assets, up from 66% a quarter earlier, followed by Financials and Materials.
On the sell side, the largest reduction was Nucor, an estimated $36.6M trimmed.
- ALPS Advisors's largest Q4 2016 buy was Eli Lilly: 558,209 shares worth $41.1M.
- ALPS Advisors added most to Energy Transfer Partners L.p. in Q4 2016, an estimated $190M increase.
- ALPS Advisors's biggest Q4 2016 reduction was Nucor, cutting an estimated $36.6M.
- ALPS Advisors fully exited NOV in Q4 2016, selling an estimated $34.2M.
- ALPS Advisors's ten largest holdings make up 52% of its $13.6B portfolio in Q4 2016.
- ALPS Advisors opened 79 new positions and closed 38 in Q4 2016.
- ALPS Advisors's portfolio value rose 11% quarter-over-quarter to $13.6B.
Based on ALPS Advisors's 13F filing for Q4 2016, filed 24 Jan 2017.